Chemotherapie kolorektaler Karzinome im Alter

V. Kächele; P. Hahn; G. Adler; T. Seufferlein

doi:10.1055/s-2004-812927

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2004; 42(10): 1189-1198
DOI: 10.1055/s-2004-812927

Übersicht

Chemotherapie kolorektaler Karzinome im Alter

Chemotherapy for Colorectal Carcinoma in the ElderlyV. Kächele¹ , P. Hahn¹ , G. Adler¹ , T. Seufferlein¹

¹Abteilung Innere Medizin I, Universitätsklinikum Ulm

Abstract

Zusammenfassung

Das kolorektale Karzinom ist mit einem mittleren Erkrankungsalter von knapp 70 Jahren überwiegend eine Erkrankung des höheren Lebensalters. Aus vorliegenden Studien zur Chemotherapie des kolorektalen Karzinoms zeigt sich, dass auch ältere Patienten sowohl von einer adjuvanten als auch palliativen zytostatischen Therapie profitieren. Im Vergleich zu jüngeren Patienten ist bei älteren Patienten in gutem Allgemeinzustand bei ähnlichem Therapieansprechen eine nur geringgradig erhöhte Toxizität zu erwarten.

Ältere Patienten sind in klinischen Studien deutlich unterrepräsentiert. Daher können die vorliegenden Daten nicht generell auf ältere Patienten mit kolorektalem Karzinom bezogen werden. Durch geriatrisches Assessment können therapierelevante Informationen zur besseren Patientenselektion erzielt werden. Auf der Grundlage eines solchen Assessments sollte bei der Vielzahl neuerer Medikamente, die derzeit in die Therapie des kolorektalen Karzinoms integriert werden, Wert darauf gelegt werden, geeignete ältere Patienten auch in klinischen Studien zu behandeln.

Abstract

With nearly 50 % of all colorectal cancers being diagnosed in patients at the age of 70 or above colorectal cancer is a disease of the elderly. In an adjuvant setting, fit elderly patients can receive the same benefit from cytotoxic therapy as younger patients with an only slightly increased toxicity.

In a palliative setting, the treatment of elderly patients with respect to clinical endpoints such as response, time to progression or overall survival is as effective as in their younger counterparts. In clinical studies, older patients are generally underrepresented and among the elderly patients involved in clinical studies there is a bias towards particularly fit patients. Therefore it is not possible to extrapolate the results of many randomized trials to all elderly patients. A Comprehensive Geriatric Assessment (CGA) should be applied to detect the diversities in the geriatric population. Based on this assessment elderly patients classified as suitable for chemotherapy should be enrolled into clinical trials for colorectal cancer.

Schlüsselwörter

Kolorektales Karzinom - Chemotherapie - Geriatrische Onkologie

Key words

colorectal cancer - chemotherapy - geriatric oncology

Full Text

References

Literatur

1 Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland - Häufigkeiten und Trends. 3. erw. aktual. Auflage Saarbrücken; 2002: 28-31
2 Levi F, Lucchini F, Negri E. et al . Mortality from major cancer sites in the European Union, 1955 - 1998. Ann Oncol. 2003; 14 490-495
3 Yancik R. Cancer burden in the aged. An epidemiologic and demographic overview. Cancer. 1997; 80 1273-1283
4 Coiffier B, Lepage E, Briere J. et al . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346 235-242
5 Schild S E, Stella P J, Geyer S M. et al . The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003; 21 3201-3206
6 Bouchardy C, Rapiti E, Fioretta G. et al . Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003; 21 3580-3587
7 Honecker F, Köhne C H, Bokemeyer C. Colorectal cancer in the elderly. Is palliative chemotherapy of value?. Drugs Aging. 2003; 20 1-11
8 Trimble E L, Carter C L, Cain D. et al . Representation of older patients in cancer treatment trials. Cancer. 1994; 74 2208-2214
9 Hutchins L F, Unger J M, Crowley J J. et al . Underrepresentation of patients 65 years of age and older in cancer treatment trials. N Engl J Med. 1999; 341 2061-2067
10 Lewis J H, Kilgore M L, Goldman. et al . Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21 1383-1389
11 Monfardini S, Sorio R, Boes G H. et al . Entry and evaluation of elderly patients in European Organisation for Research and Treatment of Cancer (EORTC) new drug-development studies. Cancer. 1995; 76 333-338
12 Yee K WL, Pater J L, Pho L. et al . Enrollment of older patients in cancer treatment trials: Why is age a barrier?. J Clin Oncol. 2003; 21 1618-1623
13 Ogle K S, Swanson G M, Woods N. et al . Cancer and comorbidity. Redefining chronic diseases. Cancer. 2000; 88 653-663
14 Yancik R, Wesley M N, Ries R AG. et al . Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients. Cancer. 1998; 82 2123-2134
15 Charlson M E, Pompei P, Ales K. et al . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40 373-383
16 Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000; 36 453-471
17 Nikolaus T. Geriatrisches Assessment. Nikolaus T Klinische Geriatrie Berlin; Springer Verlag 2000: 159-188
18 Repetto L, Fratino L, Audisio R A. et al . Comprehensive Geriatric Assessment adds information to Eastern Cooperative Oncology Group Performance Status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002; 20 494-502
19 Balducci L, Exterman M. Management of Cancer in the older person: a practical approach. The Oncologist. 2000; 5 224-237
20 Friedrich C, Kolb G, Wedding U. et al . Comprehensive geriatric assessment in the elderly cancer patient. Onkologie. 2003; 26 355-360
21 Balducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am. 2000; 14 235-250
22 Kaufman D W, Kelly J P, Rosenberg L. et al . Recent pattern of medication use in the ambulatory adult population of the United States: the Slone Survey. JAMA. 2002; 287 337-344
23 Kimmick G G, Fleming R, Muss H B. et al . Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging. 1997; 10 34-49
24 Mathijssen R H, Verweij J, de Bruijn P. et al . Effects of St.John’s wort on irinotecan metabolism. J Natl Cancer Inst. 2002; 94 1247-1249
25 Vestal R E. Aging and pharmacology. Cancer. 1997; 80 1302-1310
26 Saltz L B, Cox J V, Blanke C. et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343 905-914
27 Douillard J Y, Cunnungham D, Roth A D. et al . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet. 2000; 355 1041-1047
28 Giacchetti S, Perpoint B, Zidani R. et al . Phase III multicenter trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18 136-47
29 De Gramont A, Figer A, Seymour M. et al . Leukovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18 2938-47
30 Koehne C H, Van Cutsem E, Wils J A. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40 986. Proc Am Soc Clin Oncol. 2003; 22 1017 (Abstract)
31 Hurwitz H, Fehrenbacher L, Cartwright T. et al . Bevacizumab prolongs survival in first-line colorectal cancer: Results of a phase III trial of bevacizumab in combination with bolus IFL as a first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol. 2003; 22 3646 (Abstract)
32 Cunningham D, Humblet Y, Siena S. et al . Cetuximab (C225) alone or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2003; 22 1012 (Abstract)
33 Colorectal Cancer Collaborative Group . Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ. 2000; 321 531-535
34 Meta-Analysis Group in Cancer . Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998; 16 3537-3541
35 Köhne C H, Cunningham D, Di Constanzo F. et al . Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 Patients. Ann Oncol. 2002; 13 308-317
36 Vanhöfer U, Köhne C H. Chemotherapeutische Möglichkeiten bei metastasiertem kolorektalen Karzinom. Dtsch Ärzteblatt. 2003; 100 705-714
37 Diasio R B, Harris B E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989; 16 215-237
38 Bokemeyer C, Perry M C. Kompendium Internistische Onkologie, Teil 1. Schmoll HJ, Höffken K, Possinger K Berlin; Springer 1999: 1404
39 Sloan J A, Goldberg R M, Sargent D J. et al . Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002; 20 1491-1498
40 Becker K, Erckenbrecht J F, Häussinger D. et al . Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999; 57 475-484
41 Robben N C, Pippas A W, Moore J O. The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer. 1993; 71 493-509
42 Raida M, Schwabe W, Häusler P. et al . Prevalence of a common point mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene with the 5‘-Splice Donor Site of Intron 14 in patients with severe 5-Fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2001; 7 2832-2839
43 Van Kuilenburg A BP, Haasjes J, Richel D. et al . Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000; 6 4705-4712
44 Van Kuilenburg A BP, Muller E W, Haasjes J. et al . Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1GA mutation causing DPD-deficiency. Clin Cancer Res. 2001; 7 1149-1153
45 Köhne C H, Wils J, Lorenz M. et al . Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leukovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organisation of Research and treatment of Cancer Gastrointestinal Group Study 40 952. J Clin Oncol. 2003; 21 3721-3728
46 Stein B N, Petrelli N J, Douglass H O. et al . Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer. 1995; 75 11-17
47 Zalcberg J, Kerr D, Seymour L. et al . Haematological and Non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Eur J Cancer. 1998; 34 1871-1875
48 Chiara S, Nobile M T, Vincenti M. et al . Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998; 42 336-340
49 Daniele B, Rosati G, Pignata S. et al . Phase II study of first line chemotherapy with de Gramont schedule for elderly patients with advanced colorectal cancer. Proc Am Soc Clin Oncol. 2002; 21 2243 (Abstract)
50 Popescu R A, Norman A, Ross P J. et al . Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999; 17 2412-2418
51 Jacobson S D, Cha S, Sargent D J. et al . Tolerability, dose intensity, and benefit of 5-FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) Study. Proc Am Soc Clin Oncol. 2001; 20 1534 (Abstract)
52 Magne N, Francois E, Broisin L. et al . Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-years experience. Am J Clin Oncol. 2002; 25 126-130
53 O’Conell M J, Martenson J A, Wieand H S. et al . Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994; 331 502-507
54 Neugut A I, Fleischauer A T, Sundararajan V. et al . Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: A population-based study. J Clin Oncol. 2002; 20 2643-2650
55 Janjan N A, Khoo V S, Abbruzzese J. et al . Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999; 44 1027-1038
56 Rödel C, Grabenbauer G G, Papadopoulos T. et al . Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol. 2003; 21 3098-3104
57 Schrag D S, Cramer L D, Bach P B. et al . Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93 850-857
58 Sargent D J, Goldberg R M, Jacobson S D. et al . A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345 1091-1097
59 Iwashyna T J, Lamont E B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002; 20 3992-3998
60 Tabah-Fisch I, Maindrault-Goebel F, Benavides M. et al . Oxaliplatin is feasible, safe and active in elderly colorectal cancer (CRC) patients. Proc Am Soc Clin Oncol. 2002; 21 556 (Abstract)
61 Borner M, Schöffski P, de Wit R. et al . Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002; 38 349-358
62 Twelves C. Capecitabine as first-line treatment in colorectal cancer; pooled data from two large, phase III trials. Eur J Cancer. 2002; 38 (Suppl. 2) 15-20
63 Cassidy J, Twelves C, Van Cutsem E. et al . First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002; 13 566-575
64 Escudero P, Verge V, Feliu J. et al . A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2003; 22 3114 (Abstract)
65 Diaz-Rubio E, Sastrre J, Abad A. et al . UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. Oncology. 1999; 13 35-40
66 Feliu J, Gonzalez B aron M, Espinosa E. et al . Uracil and tegafur modulated with leucovorin. An effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer. 1997; 79 1884-1889
67 Cily C R, Clemett D, Wisemann L R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 2000; 60 895-924
68 Takimoto C H, Remick S C, Sharma S. et al . Dose-escalating and pharmacological study of Oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol. 2003; 21 2664-2672
69 Martin G, Graham L, Cunningham D. et al . Pharmacokinetics of Oxaliplatin in special populations. (Abstract). Proc Am Soc Clin Oncol. 1999; 18 729
70 Eckel F, Schmelz R, Adelsberger H. et al . Prophylaxe der Oxaliplatin-induzierten Neuropathie mit Carbamazepin. DMW. 2002; 127 78-82
71 Levi F, Zidani R, Focan C. et al . Age-independent benefit of chronotherapy with 5-fluorouracil, leucovorin and oxaliplatin in patients with metastatic colorectal cancer within multicenter randomized phase III trials. Proc Am Soc Clin Oncol. 2002; 21 1431 (Abstract)
72 Mattioli R, Reccchia F, Lippe P. et al . Bi-fractionated “folfox” as first line chemotherapy (CT) in elderly patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2003; 22 1411 (Abstract)
73 De Gramont A, Banzi M, Navarro M. et al . Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc Am Soc Clin Oncol. 2003; 22 1015 (Abstract)
74 Pizzolato J F, Saltz L B. The camptothecins. Lancet. 2003; 361 2235-2242
75 Schaaf L, Ichhpurani N, Elfring G. et al . Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol. 1997; 16 (Abstract)
76 Stemmler J, Weise A, Hacker U. et al . Weekly Irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie. 2002; 25 60-63
77 Rothenberg M L, Meropol N J, Poplin E A. et al . Mortality associated with irinotecan plus bolus Fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001; 19 3801-3807
78 Wang E, Anderson S E, Hummer A. et al . Dose intensity and toxicity of CPT-11 in geriatric metastatic colorectal cancer patients. Proc Am Soc Clin Oncol. 2002; 21 1448 (Abstract)
79 Rothenberg M L, Cox J V, DeVore R F. et al . A multicenter, phase II trial of weekly Irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 1999; 85 786-795
80 Rougier P, Mitry E, Cunningham D. et al . Is age a prognostic factor of toxicity in patients with metastatic colorectal cancer receiving irinotecan in combination with 5-FU/folinic acid. Proc Am Soc Clin Oncol. 2003; 22 1072 (Abstract)

Dr. V. Kächele

Abt. Innere Medizin I, Universitätsklinikum Ulm

Robert-Koch-Straße 8

89081 Ulm